biotech / news / / CNBC
AstraZeneca's shares fell 2% in morning trading.
The FDA advisory panel voted 6-3 against AstraZeneca's breast cancer drug camizestrant approval.
KEY POINTS
- Panel concerns focused on the SERENA-6 trial design, not camizestrant's toxicity or general safety.
- The SERENA-6 trial showed a 56% reduction in disease progression risk, but survival benefit was unclear.
- Panelists were unconvinced that early switching to camizestrant improves long-term survival versus current therapies.
- Camizestrant's limited impact means the negative vote is not material to AstraZeneca's long-term sales outlook.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →